JP2015520128A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015520128A5 JP2015520128A5 JP2015506351A JP2015506351A JP2015520128A5 JP 2015520128 A5 JP2015520128 A5 JP 2015520128A5 JP 2015506351 A JP2015506351 A JP 2015506351A JP 2015506351 A JP2015506351 A JP 2015506351A JP 2015520128 A5 JP2015520128 A5 JP 2015520128A5
- Authority
- JP
- Japan
- Prior art keywords
- ctp
- amino acid
- seq
- modified polypeptide
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 28
- 229920001184 polypeptide Polymers 0.000 claims 20
- 208000008589 Obesity Diseases 0.000 claims 4
- 239000000556 agonist Substances 0.000 claims 4
- 235000020824 obesity Nutrition 0.000 claims 4
- 229920000023 polynucleotide Polymers 0.000 claims 4
- 239000002157 polynucleotide Substances 0.000 claims 4
- 239000000018 receptor agonist Substances 0.000 claims 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 3
- 208000008466 Metabolic Disease Diseases 0.000 claims 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- 239000008103 glucose Substances 0.000 claims 3
- 206010012601 Diabetes mellitus Diseases 0.000 claims 2
- 102000025873 GPCR, family 2, glucagon receptor Human genes 0.000 claims 2
- 108010063919 GPCR, family 2, glucagon receptor Proteins 0.000 claims 2
- 108060003199 Glucagon Proteins 0.000 claims 2
- 229960004666 Glucagon Drugs 0.000 claims 2
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 claims 2
- MASNOZXLGMXCHN-ZLPAWPGGSA-N Glucagonum Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims 2
- PXZWGQLGAKCNKD-DPNMSELWSA-N MolPort-023-276-326 Chemical group C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 PXZWGQLGAKCNKD-DPNMSELWSA-N 0.000 claims 2
- 101800001388 Oxyntomodulin Proteins 0.000 claims 2
- 102400000319 Oxyntomodulin Human genes 0.000 claims 2
- 230000037406 food intake Effects 0.000 claims 2
- 235000012631 food intake Nutrition 0.000 claims 2
- 230000002068 genetic Effects 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 201000008839 post-traumatic stress disease Diseases 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- DTHNMHAUYICORS-KTKZVXAJSA-N 107444-51-9 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 1
- 210000000577 Adipose Tissue Anatomy 0.000 claims 1
- 206010057666 Anxiety disease Diseases 0.000 claims 1
- 102000011022 Chorionic Gonadotropin Human genes 0.000 claims 1
- 108010062540 Chorionic Gonadotropin Proteins 0.000 claims 1
- 229940015047 Chorionic Gonadotropin Drugs 0.000 claims 1
- 208000001380 Diabetic Ketoacidosis Diseases 0.000 claims 1
- 102100003818 GCG Human genes 0.000 claims 1
- 101710042131 GCG Proteins 0.000 claims 1
- 101700071595 GRZ1 Proteins 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 229920001850 Nucleic acid sequence Polymers 0.000 claims 1
- 101700078733 ZGLP1 Proteins 0.000 claims 1
- 229960004407 chorionic gonadotrophin Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000001603 reducing Effects 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 230000004584 weight gain Effects 0.000 claims 1
- 235000019786 weight gain Nutrition 0.000 claims 1
Claims (32)
- GLP−1/グルカゴンデュアル受容体アゴニストと、前記アゴニストのアミノ末端またはカルボキシ末端に結合した1〜5個の絨毛性ゴナドトロピンカルボキシ末端ペプチド(CTP)とを含むCTP修飾ポリペプチド。
- 前記GLP−1/グルカゴン受容体アゴニストがオキシントモジュリンであることを特徴とする請求項1に記載のCTP修飾ポリペプチド。
- 前記CTP修飾ポリペプチドのアミノ酸配列が、配列番号9、15、25、27、29、配列番号21の4〜122番目のアミノ酸配列、及び配列番号23の1〜119番目のアミノ酸配列からなる群より選択されたアミノ酸配列を含むことを特徴とする請求項2に記載のCTP修飾ポリペプチド。
- 前記CTP修飾ポリペプチドが、シグナルペプチドを含まないことを特徴とする請求項1または2に記載のCTP修飾ポリペプチド。
- 前記CTP修飾ポリペプチドのアミノ酸配列が、配列番号9の27〜119番目のアミノ酸配列、配列番号15の27〜147番目のアミノ酸配列、配列番号21の30〜122番目のアミノ酸配列、配列番号23の27〜119番目のアミノ酸配列、配列番号25の26〜147番目のアミノ酸配列、配列番号27の27〜175番目のアミノ酸配列、及び配列番号29の27〜203番目のアミノ酸配列からなる群より選択されたアミノ酸配列を含むことを特徴とする請求項2または4に記載のCTP修飾ポリペプチド。
- 少なくとも1つのCTPのアミノ酸配列が、配列番号1および配列番号2からなる群より選択されることを特徴とする請求項1または2に記載のCTP修飾ポリペプチド。
- 少なくとも1つのCTPがグリコシル化されていることを特徴とする請求項1〜6のいずれか一項に記載のCTP修飾ポリペプチド。
- 少なくとも1つのCTPが短縮化されていることを特徴とする請求項1または2に記載のCTP修飾ポリペプチド。
- 少なくとも1つのCTPが、リンカーを介して前記アゴニストに結合していることを特徴とする請求項1または2に記載のCTP修飾ポリペプチド。
- 前記リンカーがペプチド結合であることを特徴とする請求項9に記載のCTP修飾ポリペプチド。
- 請求項1〜10のいずれか一項に記載のCTP修飾ポリペプチドを含む医薬組成物。
- 請求項1〜10のいずれか一項に記載のCTP修飾ポリペプチドをコードするポリヌクレオチド。
- 前記ポリヌクレオチドのヌクレオチド配列が、配列番号8、14、20、22、24、26、及び28からなる群から選択されたヌクレオチド配列を含むことを特徴とする請求項12に記載のポリヌクレオチド。
- 請求項12または13に記載のポリヌクレオチドを含む発現ベクター。
- 請求項14に記載の発現ベクターを含む細胞または医薬組成物。
- 対象における耐糖性を誘導するための、対象における望ましくない体重増加を防止するための、対象における食物摂取を阻害、減少または抑制するための、対象における肥満を治療するための、対象におけるII型糖尿病を治療するための、または、対象における代謝性障害を治療するための医薬を製造するための、GLP−1/グルカゴンデュアル受容体アゴニストと、前記アゴニストのアミノ末端またはカルボキシ末端に結合した1〜5個の絨毛性ゴナドトロピンカルボキシ末端ペプチド(CTP)とを含むCTP修飾ポリペプチドの使用。
- 前記GLP−1/グルカゴン受容体アゴニストがオキシントモジュリンであることを特徴とする請求項16に記載の使用。
- 前記CTP修飾ポリペプチドのアミノ酸配列が、配列番号9、15、25、27、29、配列番号21の4〜122番目のアミノ酸配列、及び配列番号23の1〜119番目のアミノ酸配列からなる群より選択されたアミノ酸配列を含むことを特徴とする請求項17に記載の使用。
- 前記CTP修飾ポリペプチドが、シグナルペプチドを含まないことを特徴とする請求項16または17に記載の使用。
- 前記CTP修飾ポリペプチドのアミノ酸配列が、配列番号9の27〜119番目のアミノ酸配列、配列番号15の27〜147番目のアミノ酸配列、配列番号21の30〜122番目のアミノ酸配列、配列番号23の27〜119番目のアミノ酸配列、配列番号25の26〜147番目のアミノ酸配列、配列番号27の27〜175番目のアミノ酸配列、及び配列番号29の27〜203番目のアミノ酸配列からなる群より選択されたアミノ酸配列を含むことを特徴とする請求項17または19に記載の使用。
- 少なくとも1つのCTPのアミノ酸配列が、配列番号1および配列番号2からなる群より選択されることを特徴とする請求項16または17に記載の使用。
- 少なくとも1つのCTPがグリコシル化されていることを特徴とする請求項16〜21のいずれか一項に記載の使用。
- 少なくとも1つのCTPが短縮化されていることを特徴とする請求項16または17に記載の使用。
- 少なくとも1つのCTPが、リンカーを介して前記アゴニストに結合していることを特徴とする請求項16または17に記載の使用。
- 前記リンカーがペプチド結合であることを特徴とする請求項24に記載の使用。
- 前記体重増加が、前記対象に肥満を発生させるか、前記対象の心理状態に起因するか、または前記対象における肥満になりやすい遺伝的素因に起因することを特徴とする請求項16に記載の使用。
- 前記心理状態が、うつ病、不安症、または心的外傷後ストレス障害(PTSD)であることを特徴とする請求項26に記載の使用。
- 前記対象による食物摂取を阻害、減少または抑制することにより、前記対象に肥満が発生する可能性を減少させるようにしたことを特徴とする請求項16に記載の使用。
- 前記対象が、肥満になりやすい遺伝的素因を有していることを特徴とする請求項16、26、または28のいずれか一項に記載の使用。
- 肥満を治療することにより、前記対象の体重または体脂肪が減少するようにしたことを特徴とする請求項16、26、28、または29のいずれか一項に記載の使用。
- 前記代謝性障害が、糖尿病性ケトアシドーシス、真性糖尿病、またはそれらの組合せであることを特徴とする請求項16に記載の使用。
- 前記代謝性障害が、前記対象におけるインスリンの欠乏とグルコースの過剰により生じることを特徴とする請求項16に記載の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261635483P | 2012-04-19 | 2012-04-19 | |
US61/635,483 | 2012-04-19 | ||
PCT/IL2013/050332 WO2013157002A1 (en) | 2012-04-19 | 2013-04-17 | Long-acting oxyntomodulin variants and methods of producing same |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2015520128A JP2015520128A (ja) | 2015-07-16 |
JP2015520128A5 true JP2015520128A5 (ja) | 2016-06-16 |
Family
ID=49383021
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015506351A Pending JP2015520128A (ja) | 2012-04-19 | 2013-04-17 | 長時間作用性オキシントモジュリン変異体とその作製方法 |
Country Status (18)
Country | Link |
---|---|
US (2) | US9522945B2 (ja) |
EP (1) | EP2838552A4 (ja) |
JP (1) | JP2015520128A (ja) |
KR (1) | KR20150008137A (ja) |
CN (1) | CN104487082A (ja) |
AU (1) | AU2013250711A1 (ja) |
BR (1) | BR112014025951A2 (ja) |
CA (1) | CA2870650A1 (ja) |
CL (1) | CL2014002791A1 (ja) |
CO (1) | CO7200249A2 (ja) |
EA (1) | EA201491898A1 (ja) |
HK (1) | HK1207564A1 (ja) |
IL (1) | IL235184A0 (ja) |
MX (1) | MX2014012625A (ja) |
MY (1) | MY167814A (ja) |
PE (1) | PE20142405A1 (ja) |
SG (1) | SG11201406671RA (ja) |
WO (1) | WO2013157002A1 (ja) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140113860A1 (en) | 2006-02-03 | 2014-04-24 | Prolor Biotech Ltd. | Long-acting polypeptides and methods of producing and administering same |
US10221228B2 (en) | 2006-02-03 | 2019-03-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
US8946155B2 (en) | 2006-02-03 | 2015-02-03 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
US9458444B2 (en) | 2006-02-03 | 2016-10-04 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
US10351615B2 (en) | 2006-02-03 | 2019-07-16 | Opko Biologics Ltd. | Methods of treatment with long-acting growth hormone |
US9249407B2 (en) | 2006-02-03 | 2016-02-02 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
US8048849B2 (en) | 2006-02-03 | 2011-11-01 | Modigene, Inc. | Long-acting polypeptides and methods of producing same |
US20150038413A1 (en) | 2006-02-03 | 2015-02-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
US9663778B2 (en) | 2009-07-09 | 2017-05-30 | OPKO Biologies Ltd. | Long-acting coagulation factors and methods of producing same |
US10166295B2 (en) | 2011-06-02 | 2019-01-01 | Opko Biologics Ltd. | Pegylated OXM variants |
LT2718318T (lt) | 2011-06-10 | 2018-10-25 | Hanmi Science Co., Ltd. | Nauji oksintomodulino dariniai ir farmacinė kompozicija, apimanti šiuos darinius, nutukimo gydymui |
HUE042585T2 (hu) | 2011-06-17 | 2019-07-29 | Hanmi Science Co Ltd | Oxintomodulint és immunglobulin-fragmentumot tartalmazó konjugátum és alkalmazása |
MY167814A (en) | 2012-04-19 | 2018-09-26 | Opko Biologics Ltd | Long-acting oxyntomodulin variants and methods of producing same |
JP6290193B2 (ja) | 2012-06-04 | 2018-03-07 | オプコ バイオロジクス リミテッド | ペグ化oxm変異体 |
KR101968344B1 (ko) | 2012-07-25 | 2019-04-12 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물 |
KR101993393B1 (ko) | 2012-11-06 | 2019-10-01 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물 |
SG10201602801YA (en) | 2012-11-06 | 2016-05-30 | Hanmi Pharm Ind Co Ltd | Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment |
BR122020018510B1 (pt) * | 2012-11-20 | 2023-03-14 | Opko Biologics Ltd | Método para aumentar incrementalmente o tamanho hidrodinâmico de um fator de coagulação ativado viia |
US20150158926A1 (en) | 2013-10-21 | 2015-06-11 | Opko Biologics, Ltd. | Long-acting polypeptides and methods of producing and administering same |
TWI772252B (zh) | 2014-09-16 | 2022-08-01 | 南韓商韓美藥品股份有限公司 | 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途 |
WO2016061149A1 (en) * | 2014-10-14 | 2016-04-21 | Medgenics Medical Israel Ltd. | Genetically-modified micro-organ secreting a therapeutic peptide and methods of use thereof |
TWI746427B (zh) * | 2014-12-10 | 2021-11-21 | 以色列商歐科生物製品有限公司 | 製造長效ctp修飾的多肽之方法 |
KR102418477B1 (ko) | 2014-12-30 | 2022-07-08 | 한미약품 주식회사 | 글루카곤 유도체 |
ES2893616T3 (es) | 2015-06-19 | 2022-02-09 | Opko Biologics Ltd | Factores de coagulación de acción prolongada y métodos para la producción de los mismos |
AR105284A1 (es) * | 2015-07-10 | 2017-09-20 | Sanofi Sa | Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón |
AU2017296352A1 (en) | 2016-07-11 | 2019-02-21 | Opko Biologics Ltd. | Long-acting coagulation factor VII and methods of producing same |
CN108299553B (zh) * | 2017-01-13 | 2021-07-16 | 博瑞生物医药(苏州)股份有限公司 | 胃泌酸调节素修饰物 |
BR112020003319A2 (pt) * | 2017-08-16 | 2020-08-25 | Dong-A St Co., Ltd. | análogo de peptídeo de oxintomodulina acilada |
KR20210031455A (ko) * | 2018-06-11 | 2021-03-19 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 치환된 헤테로환 융합 감마-카르볼린 합성 |
US20200262887A1 (en) | 2018-11-30 | 2020-08-20 | Opko Ireland Global Holdings, Ltd. | Oxyntomodulin peptide analog formulations |
Family Cites Families (129)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
NL154599B (nl) | 1970-12-28 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
NL171930C (nl) | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
JPS5781447A (en) | 1980-11-11 | 1982-05-21 | Toyo Jozo Co Ltd | Human chorionic gonadotropic hormone c-terminal fragment |
US4853332A (en) | 1982-10-19 | 1989-08-01 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins |
US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
DE3421468A1 (de) | 1984-06-08 | 1985-12-19 | Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim | Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung |
US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
US4911691A (en) | 1984-09-21 | 1990-03-27 | Menlo Care, Inc. | Assembly for adminstering IV solution |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
DE122007000007I1 (de) | 1986-04-09 | 2007-05-16 | Genzyme Corp | Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern |
US5118666A (en) | 1986-05-05 | 1992-06-02 | The General Hospital Corporation | Insulinotropic hormone |
US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
DE68917883T2 (de) | 1988-05-06 | 1995-02-23 | Toray Industries | Stabile interferon-beta-zusammensetzung. |
US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
US6225449B1 (en) | 1991-10-04 | 2001-05-01 | Washington University | Hormone analogs with multiple CTP extensions |
US5792460A (en) * | 1989-02-21 | 1998-08-11 | Washington University | Modified glycoprotein hormones having a CTP at the amino terminus |
US5705478A (en) | 1989-02-21 | 1998-01-06 | Washington University | Covalently linked β subunits of the glycoprotein hormones as antagonists |
US5338835A (en) | 1989-02-21 | 1994-08-16 | Washington University | CTP-extended form of FSH |
DK0461200T3 (da) | 1989-02-21 | 1997-03-10 | Univ Washington | Modificerede former af reproduktionshormoner |
US5464764A (en) | 1989-08-22 | 1995-11-07 | University Of Utah Research Foundation | Positive-negative selection methods and vectors |
US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
US7217689B1 (en) | 1989-10-13 | 2007-05-15 | Amgen Inc. | Glycosylation analogs of erythropoietin |
US5126324A (en) | 1990-06-07 | 1992-06-30 | Genentech, Inc. | Method of enhancing growth in patients using combination therapy |
US6028177A (en) | 1991-10-04 | 2000-02-22 | Washington University | Methods of detecting single-chain forms of the glycoprotein hormone quartet |
US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
WO1994024148A1 (en) | 1993-04-20 | 1994-10-27 | Washington University | Modified protein and peptide pharmaceuticals |
US5605976A (en) | 1995-05-15 | 1997-02-25 | Enzon, Inc. | Method of preparing polyalkylene oxide carboxylic acids |
US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US6737515B2 (en) | 1993-11-19 | 2004-05-18 | Washington University | Follicle stimulating hormone-glycosylation analogs |
US6238890B1 (en) | 1994-02-18 | 2001-05-29 | Washington University | Single chain forms of the glycoprotein hormone quartet |
US5935924A (en) | 1994-04-15 | 1999-08-10 | Genentech, Inc. | Treatment of congestive heart failure |
US5541110A (en) | 1994-05-17 | 1996-07-30 | Bristol-Myers Squibb | Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica |
BR9506313A (pt) | 1994-08-12 | 1997-08-05 | Univ Washington | Formas de cadeia simples do quarteto de hormônio de glicoproteína |
US6083725A (en) | 1996-09-13 | 2000-07-04 | Transkaryotic Therapies, Inc. | Tranfected human cells expressing human α-galactosidase A protein |
US20050032211A1 (en) | 1996-09-26 | 2005-02-10 | Metabogal Ltd. | Cell/tissue culturing device, system and method |
TW518235B (en) | 1997-01-15 | 2003-01-21 | Akzo Nobel Nv | A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage |
US6310183B1 (en) | 1997-09-10 | 2001-10-30 | Novo Nordisk A/S | Coagulation factor VIIa composition |
US6103501A (en) | 1997-11-17 | 2000-08-15 | Washington University | Single chain glycoprotein hormones comprising two β and one α subunits and recombinant production thereof |
PT1121382E (pt) | 1998-10-16 | 2006-10-31 | Biogen Idec Inc | Proteinas de fusao do interferao beta e as respectivas utilizacoes |
US6514729B1 (en) | 1999-05-12 | 2003-02-04 | Xencor, Inc. | Recombinant interferon-beta muteins |
PE20010288A1 (es) | 1999-07-02 | 2001-03-07 | Hoffmann La Roche | Derivados de eritropoyetina |
US20010028895A1 (en) | 2000-02-04 | 2001-10-11 | Bisgaier Charles L. | Methods of treating alzheimer's disease |
US20020127652A1 (en) | 2000-02-11 | 2002-09-12 | Schambye Hans Thalsgard | Follicle stimulating hormones |
US7094566B2 (en) | 2000-03-16 | 2006-08-22 | Amgen Inc., | IL-17 receptor like molecules and uses thereof |
US20030036181A1 (en) | 2000-06-30 | 2003-02-20 | Okkels Jens Sigurd | Peptide extended glycosylated polypeptides |
US7118737B2 (en) | 2000-09-08 | 2006-10-10 | Amylin Pharmaceuticals, Inc. | Polymer-modified synthetic proteins |
US6706289B2 (en) | 2000-10-31 | 2004-03-16 | Pr Pharmaceuticals, Inc. | Methods and compositions for enhanced delivery of bioactive molecules |
CN1268641C (zh) | 2000-11-10 | 2006-08-09 | 普罗蒂奥制药公司 | 载脂蛋白类似物 |
EP2062593A3 (en) | 2000-12-01 | 2011-08-17 | Takeda Pharmaceutical Company Limited | Method for producing preparation containing bioactive peptide |
CZ308214B6 (cs) | 2000-12-07 | 2020-03-04 | Eli Lilly And Company | GLP-1 fúzní proteiny |
KR101229995B1 (ko) | 2000-12-11 | 2013-02-06 | 씨제이 주식회사 | 생체내 에리스로포이에틴 활성이 증진된 융합단백질 |
DE60117919T2 (de) | 2000-12-11 | 2006-12-14 | Cheil Jedang Corp. | Fusionsprotein mit verbesserter in vivo erythropoietinwirkung |
WO2002053136A1 (fr) | 2000-12-28 | 2002-07-11 | Takeda Chemical Industries, Ltd. | Preparations a liberation soutenue |
US6987172B2 (en) | 2001-03-05 | 2006-01-17 | Washington University In St. Louis | Multifunctional single chain glycoprotein hormones comprising three or more β subunits |
US6887462B2 (en) | 2001-04-09 | 2005-05-03 | Chiron Corporation | HSA-free formulations of interferon-beta |
WO2002085311A2 (en) | 2001-04-25 | 2002-10-31 | Acevedo Hernan F | Hcg formulation |
US6824769B2 (en) | 2001-08-28 | 2004-11-30 | Vertex Pharmaceuticals Incorporated | Optimal compositions and methods thereof for treating HCV infections |
GB0121709D0 (en) | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
US7795210B2 (en) | 2001-10-10 | 2010-09-14 | Novo Nordisk A/S | Protein remodeling methods and proteins/peptides produced by the methods |
ES2381104T3 (es) | 2001-10-29 | 2012-05-23 | Crucell Holland B.V. | Métodos y medios para producir proteínas con modificaciones postraduccionales predeterminadas |
KR100467751B1 (ko) | 2001-12-03 | 2005-01-24 | 씨제이 주식회사 | 생체내 에리스로포이에틴 활성이 증진된 융합단백질 |
EP2261250B1 (en) | 2001-12-21 | 2015-07-01 | Human Genome Sciences, Inc. | GCSF-Albumin fusion proteins |
US7081446B2 (en) | 2002-01-31 | 2006-07-25 | The Trustees Of Columbia University In The City Of New York | Long-acting follicle stimulating hormone analogues and uses thereof |
US7173113B2 (en) | 2002-01-31 | 2007-02-06 | The Trustees Of Columbia University In The City Of New York | Long-acting hormone and growth factor compositions and uses thereof |
GB0206048D0 (en) | 2002-03-14 | 2002-04-24 | Croda Int Plc | Use |
GB2403476A (en) | 2002-05-13 | 2005-01-05 | Modigenetech Ltd | CTP-extended erythropoietin |
US20070298041A1 (en) | 2002-06-28 | 2007-12-27 | Tomlinson Ian M | Ligands That Enhance Endogenous Compounds |
US20070025965A1 (en) | 2002-07-17 | 2007-02-01 | Lobb Roy R | Therapies for renal failure using interferon-beta |
US7459435B2 (en) | 2002-08-29 | 2008-12-02 | Hoffmann-La Roche Inc. | Treatment of disturbances of iron distribution |
US8129330B2 (en) | 2002-09-30 | 2012-03-06 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
US7459436B2 (en) | 2002-11-22 | 2008-12-02 | Hoffmann-La Roche Inc. | Treatment of disturbances of iron distribution |
CA2516339A1 (en) | 2003-02-19 | 2004-09-02 | Takeda Pharmaceutical Company Limited | Dispersing agent for sustained-release preparation |
WO2004089280A2 (en) | 2003-04-08 | 2004-10-21 | Yeda Research And Development Co. Ltd. | Reversible pegylated drugs |
MXPA05010773A (es) | 2003-04-09 | 2005-12-12 | Neose Technologies Inc | Metodos de glicopegilacion y proteinas/peptidos producidos por los metodos. |
WO2005035761A1 (en) * | 2003-10-16 | 2005-04-21 | Compugen Ltd. | Splice variants of preproglucagon, glucagon-like peptide-1 and oxyntomodulin |
US7649084B2 (en) | 2003-11-12 | 2010-01-19 | University Of Georgia Research Foundation, Inc. | Recombinant glycoproteins related to feline thyrotropin |
EP1696947B1 (en) | 2003-12-19 | 2014-02-26 | F.Hoffmann-La Roche Ag | Use of erythropoietin in the treatment of disturbances of iron distribution in chronic inflammatory intestinal diseases |
ES2357132T3 (es) | 2004-03-19 | 2011-04-19 | Baxter International Inc. | Factor ixa para el tratamiento de trastornos hemorrágicos. |
ATE469216T1 (de) | 2004-08-17 | 2010-06-15 | Csl Behring Gmbh | Modifizierte vitamin-k-abhängige polypeptide |
CA2585507A1 (en) | 2004-09-27 | 2006-04-06 | Cornell Research Foundation, Inc. | Recombinant bifunctional protein of human lutropin receptor and human chorionic gonadotropin b-subunit and uses thereof |
CN101724071A (zh) | 2004-10-08 | 2010-06-09 | 杜门蒂斯有限公司 | 抗肿瘤坏死因子受体1的单域抗体及其使用方法 |
GB0521621D0 (en) | 2005-10-24 | 2005-11-30 | Domantis Ltd | Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases |
EP1728798A1 (en) | 2005-06-01 | 2006-12-06 | ZLB Behring GmbH | Coagulation factor X polypeptides with modified activation properties |
DK1891105T3 (da) | 2005-06-13 | 2012-07-16 | Imp Innovations Ltd | Hidtil ukendte forbindelser og deres påvirkninger på spiseadfærd |
US8759290B2 (en) | 2005-10-18 | 2014-06-24 | Biocon Limited | Oral glucagon-like peptide conjugates for metabolic diseases |
US20150038413A1 (en) | 2006-02-03 | 2015-02-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
US8759292B2 (en) | 2006-02-03 | 2014-06-24 | Prolor Biotech, Llc | Long-acting coagulation factors and methods of producing same |
US20140113860A1 (en) | 2006-02-03 | 2014-04-24 | Prolor Biotech Ltd. | Long-acting polypeptides and methods of producing and administering same |
US8476234B2 (en) * | 2006-02-03 | 2013-07-02 | Prolor Biotech Inc. | Long-acting coagulation factors and methods of producing same |
US9458444B2 (en) | 2006-02-03 | 2016-10-04 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
US8946155B2 (en) | 2006-02-03 | 2015-02-03 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
US7553941B2 (en) | 2006-02-03 | 2009-06-30 | Modigene Inc | Long-acting polypeptides and methods of producing same |
US8048848B2 (en) | 2006-02-03 | 2011-11-01 | Prolor Biotech Ltd. | Long-acting interferons and derivatives thereof and methods thereof |
US8304386B2 (en) | 2006-02-03 | 2012-11-06 | Prolor Biotech, Inc. | Long-acting growth hormone and methods of producing same |
US8450269B2 (en) | 2006-02-03 | 2013-05-28 | Prolor Biotech Ltd. | Long-acting growth hormone and methods of producing same |
US10351615B2 (en) | 2006-02-03 | 2019-07-16 | Opko Biologics Ltd. | Methods of treatment with long-acting growth hormone |
US8048849B2 (en) | 2006-02-03 | 2011-11-01 | Modigene, Inc. | Long-acting polypeptides and methods of producing same |
WO2007100535A2 (en) | 2006-02-22 | 2007-09-07 | Merck & Co., Inc. | Oxyntomodulin derivatives |
TW200806317A (en) | 2006-03-20 | 2008-02-01 | Wyeth Corp | Methods for reducing protein aggregation |
AT505262A1 (de) | 2007-06-12 | 2008-12-15 | Apeiron Biolog Forschungs Und | Rekombinantes ace2 polypeptid |
WO2009105141A2 (en) | 2007-12-05 | 2009-08-27 | Novozymes A/S | Polypeptides having endoglucanase activity and polynucleotides encoding same |
RU2526804C2 (ru) | 2008-08-06 | 2014-08-27 | Ново Нордиск Хелс Кеа Аг | Конъюгированные белки с пролонгированным действием in vivo |
US8680263B2 (en) | 2008-09-19 | 2014-03-25 | Nektar Therapeutics | Carbohydrate-based drug delivery polymers and conjugates thereof |
CN102413990A (zh) | 2009-02-27 | 2012-04-11 | 钴领无限公司 | 模块化自动工具配送机 |
US8828953B2 (en) | 2009-04-20 | 2014-09-09 | NaZura BioHealth, Inc. | Chemosensory receptor ligand-based therapies |
DE102009031992A1 (de) | 2009-07-06 | 2011-01-13 | Paul Hartmann Ag | Vorrichtung zur Unterdrucktherapie von Wunden |
US9663778B2 (en) | 2009-07-09 | 2017-05-30 | OPKO Biologies Ltd. | Long-acting coagulation factors and methods of producing same |
AR079344A1 (es) * | 2009-12-22 | 2012-01-18 | Lilly Co Eli | Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad |
AR079345A1 (es) | 2009-12-22 | 2012-01-18 | Lilly Co Eli | Analogo peptidico de oxintomodulina |
KR101382593B1 (ko) | 2010-07-21 | 2014-04-10 | 한미사이언스 주식회사 | 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물 |
CA2837710C (en) | 2011-06-02 | 2022-11-08 | Prolor Biotech Inc. | Pegylated oxyntomodulin conjugates with improved linkers |
MY167814A (en) | 2012-04-19 | 2018-09-26 | Opko Biologics Ltd | Long-acting oxyntomodulin variants and methods of producing same |
JP6290193B2 (ja) | 2012-06-04 | 2018-03-07 | オプコ バイオロジクス リミテッド | ペグ化oxm変異体 |
BR122020018510B1 (pt) | 2012-11-20 | 2023-03-14 | Opko Biologics Ltd | Método para aumentar incrementalmente o tamanho hidrodinâmico de um fator de coagulação ativado viia |
US20150158926A1 (en) | 2013-10-21 | 2015-06-11 | Opko Biologics, Ltd. | Long-acting polypeptides and methods of producing and administering same |
-
2013
- 2013-04-17 MY MYPI2014002960A patent/MY167814A/en unknown
- 2013-04-17 CA CA2870650A patent/CA2870650A1/en not_active Abandoned
- 2013-04-17 BR BR112014025951A patent/BR112014025951A2/pt not_active IP Right Cessation
- 2013-04-17 EP EP13778848.5A patent/EP2838552A4/en not_active Withdrawn
- 2013-04-17 EA EA201491898A patent/EA201491898A1/ru unknown
- 2013-04-17 CN CN201380032217.4A patent/CN104487082A/zh active Pending
- 2013-04-17 SG SG11201406671RA patent/SG11201406671RA/en unknown
- 2013-04-17 WO PCT/IL2013/050332 patent/WO2013157002A1/en active Application Filing
- 2013-04-17 AU AU2013250711A patent/AU2013250711A1/en not_active Abandoned
- 2013-04-17 MX MX2014012625A patent/MX2014012625A/es unknown
- 2013-04-17 KR KR1020147032422A patent/KR20150008137A/ko not_active Application Discontinuation
- 2013-04-17 JP JP2015506351A patent/JP2015520128A/ja active Pending
- 2013-04-17 US US14/395,441 patent/US9522945B2/en active Active
- 2013-04-17 PE PE2014001683A patent/PE20142405A1/es not_active Application Discontinuation
-
2014
- 2014-10-16 CL CL2014002791A patent/CL2014002791A1/es unknown
- 2014-10-19 IL IL235184A patent/IL235184A0/en unknown
- 2014-11-11 CO CO14249267A patent/CO7200249A2/es unknown
-
2015
- 2015-08-24 HK HK15108167.3A patent/HK1207564A1/xx unknown
-
2016
- 2016-10-05 US US15/285,583 patent/US20170088598A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2015520128A5 (ja) | ||
JP6200025B2 (ja) | 心臓病の処置 | |
Lau et al. | Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide | |
Yabe et al. | Two incretin hormones GLP-1 and GIP: comparison of their actions in insulin secretion and β cell preservation | |
Parthier et al. | Passing the baton in class B GPCRs: peptide hormone activation via helix induction? | |
Okerson et al. | The cardiovascular effects of GLP‐1 receptor agonists | |
JP2011526303A5 (ja) | ||
Imura et al. | The natriuretic peptide system in the brain: implications in the central control of cardiovascular and neuroendocrine functions. | |
Martin et al. | Incretin‐based therapies–review of the physiology, pharmacology and emerging clinical experience | |
Patterson et al. | A novel human-based receptor antagonist of sustained action reveals body weight control by endogenous GLP-1 | |
JP2013517307A5 (ja) | ||
JP2014526441A5 (ja) | ||
JP2014504597A (ja) | アシル化グルカゴン類似体とインスリン類似体の組合せ物 | |
Persaud | Islet G-protein coupled receptors: therapeutic potential for diabetes | |
JP2012070740A5 (ja) | ||
RU2015127780A (ru) | Агонисты рецепторов глюкагона/glp-1 для лечения ожирения | |
JP2010031018A5 (ja) | ||
Lund et al. | Emerging GLP-1 receptor agonists | |
CN107106680A (zh) | 具备双受体激动剂活性的融合蛋白 | |
JP2016512205A5 (ja) | ||
Shah | GPR119 agonists: a promising new approach for the treatment of type 2 diabetes and related metabolic disorders | |
Simmons et al. | Treatment with glucagon-like Peptide-1 agonist exendin-4 in a patient with hypothalamic obesity secondary to intracranial tumor | |
Rowzee et al. | Glucagon-like peptide-1 gene therapy | |
EP3010531A1 (en) | Novel uses of glp-1 receptor agonists in patients treated with insulin and/or suffering from type 1 diabetes | |
Borner et al. | Corrination of a GLP-1 receptor agonist for glycemic control without emesis |